BIXT
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.02 | $0 | -$247,837 |
| 2025 Q4 | -0.01 | $0 | -$252,130 |
| 2025 Q3 | -0.00 | $0 | -$26,315 |
| 2025 Q2 | 0.00 | $0 | -$95,849 |
| 2025 Q1 | -152.37 | $0 | -$167,323 |
| 2024 Q4 | -0.00 | $0 | $31,982 |
| 2024 Q3 | -0.00 | $0 | $21,150 |
| 2024 Q2 | -0.00 | $0 | -$55,501 |